Abbott Laboratories ( ($ABT) ) has released its Q4 earnings. Here is a breakdown of the information Abbott Laboratories presented to its ...

Abbott Laboratories ABT faced industry-wide challenges that exerted pressure on its profit margins. Factors such as rising ...

On Wednesday, Abbott Laboratories (NYSE ... Organic growth, excluding COVID-19 testing-related sales was 10.1%. Adjusted diluted earnings per share were $1.34, in line with the analyst estimates ...

His fears were that Abbott (NYSE:ABT) might pull the product entirely rather than risk further lawsuits—just like Johnson & ...

A high throughput, highly automated test system for blood screening ... and documenting for every run. ABBOTT PRISM is designed to increase lab efficiency. It reduces manual steps and checks ...

The outlook and technical action suggest Abbott Laboratories (NYSE ... in below consensus partly because of weakness in COVID-19 testing, but organic growth is double-digit, and all segments ...

Many Abbott Laboratories ( NYSE:ABT ) insiders ditched their stock over the past year, which may be of interest to ...

Abbott also currently offers the FDA-cleared molecular Alinity M STI assay to detect and differentiate between Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma ...

Worldwide COVID-19 testing sales were $176 million in the ... 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%. Abbott Laboratories expects first quarter 2025 adjusted EPS of $1.05 ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...